At Rockefeller University in New York, researchers have turned the tables on one of tuberculosis's cleverest survival tricks. The bacterium that causes TB—Mycobacterium tuberculosis—has mutated to resist rifampicin, the antibiotic that forms the backbone of modern TB treatment. But in a finding published in Nature Microbiology, scientists discovered that the most common resistance mutation, called βS450L, creates a fatal flaw: it makes the bacteria's own machinery slower and more vulnerable to attack.
Tuberculosis remains the world's deadliest infectious disease, killing over one million people each year. Rifampicin has historically been the weapon of choice against it, binding to the bacteria's RNA polymerase—the enzyme that transcribes DNA into RNA and drives all the bacterium's essential functions. As drug-resistant strains have spread, that option has begun to slip away. "So as Rif resistance slowly makes this drug unusable, a lot of lives are in danger," says Kathryn Eckartt, a Ph.D. student in the Laboratory of Host-Pathogen Biology at Rockefeller, now a postdoctoral fellow at Weill Medical College.
The breakthrough hinges on a principle researchers have long suspected but never fully proven: that when bacteria mutate to evade one drug, the change often disrupts their core machinery and creates new weak points. The βS450L mutation blocks rifampicin from binding to RNA polymerase, protecting the bacteria from that antibiotic. But the change comes with a cost. Elizabeth Campbell and Seth Darst showed that the altered enzyme functions more slowly, frequently pausing, stalling, or prematurely terminating transcription. Bacteria carrying this mutation proved particularly sensitive to disruptions in 150 other genes.
The crucial question was why. If the vulnerabilities were merely a side effect of sluggish bacteria, they would be nearly impossible to target with precision drugs. But if the mutant enzyme's sluggish transcription machinery directly drove the weaknesses, that could provide a blueprint for new therapies. Through collaboration with Shixin Liu's Laboratory of Nanoscale Biophysics and Biochemistry, Jeremy Rock's team compared βS450L against two other common rifampicin-resistance mutations that produce the opposite effect—fast, pause-resistant RNA polymerase. By examining these contrasts, they proved the vulnerabilities in βS450L were directly linked to its slow transcription, not a mere side effect.
The team discovered something equally important: bacteria carrying βS450L become unusually dependent on pathways that produce thiamine and branched-chain amino acids. They traced this dependency to the mutant's pause-prone RNA polymerase disrupting a regulatory RNA sequence positioned before the ilvB1 gene—a molecular switch that normally senses nutrient availability. The sluggish enzyme essentially leaves the bacteria unable to properly regulate genes essential for survival.
"We're developing a strategy to stay ahead of drug resistance," says Jeremy Rock, head of the laboratory. "With combination therapies, we could exploit the fact that a mutation that helps the bacteria survive one antibiotic renders it vulnerable to another." For Vanisha Munsamy-Govender, a laboratory manager who previously worked with TB patients in South Africa, the implications are personal. The findings also suggest that future therapies may need to be tailored to specific resistance mutations, since even different fast mutations create distinct vulnerability profiles. The work offers hope that what makes tuberculosis resistant can also be what makes it defeatable.